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 Objectives To investigate the efficacy and safety profile of bevacizumab in 
combination with irinotecan in Hong Kong Chinese patients 
with recurrent malignant glioma and to determine whether their 
response differed from that reported in other populations.
 Design Retrospective study.  
 Setting Two private clinics and a public hospital in Hong Kong.
 Patients Fourteen individuals who presented with recurrent glioma 
presenting to the hospital between November 2005 and 
November 2009. 
 Intervention Salvage therapy with bevacizumab (10 mg/kg) and irinotecan 
(125 mg/m2 [340 mg/m2 for those taking enzyme-inducing 
antiepileptic drugs]) on a 14-day schedule.
 Results A radiological response was observed in 12 (86%) of the 
patients, four (33%) of whom had a complete response. The 
median progression-free survival was 6 (range, 1-15) months; 
71% remained progression-free at 6 months. The median 
overall survival was 18 (range, 9-61) months. The most common 
adverse events during the bevacizumab and irinotecan 
treatment period were haematological; five patients had grade 
2/3 adverse events. Pulmonary embolism occurred in two 
patients, one of whom died. Intracranial haemorrhage was not 
detected in any of the 14 treated patients. 
 Conclusions Bevacizumab plus irinotecan was at least as effective at treating 
Chinese patients with recurrent glioma as previously reported in 
clinical trials in different patient populations.
Using bevacizumab in the fight against malignant 
glioma: first results in Asian patients
O R I G I N A L
A R T I C L E
Key words
Antineoplastic combined chemotherapy 
protocols; Brain neoplasms; Glioblastoma; 
Neoplasm recurrence, local; Treatment 
outcome
Hong Kong Med J 2011;17:274-9
Department of Surgery, Li Ka Shing 
Faculty of Medicine, University of 
Hong Kong, Queen Mary Hospital, 102 
Pokfulam Road, Hong Kong
JKS Pu, FRCS(SN)(Edin), FHKAM (Surgery)
GKB Ng, BSc, MPH
GKK Leung, MB, BS, MS
KN Hung, FRCS (Edin), FHKAM (Surgery)
Room 1205-6, Argyle Centre 1, 
Mongkok, Hong Kong
RTT Chan, FRCR, FHKAM (Radiology)
Room 1705, Grand Centre, 8 Humphreys 
Avenue, Tsimshatsui, Hong Kong
CF Fung, FRCS (Edin, Glasg), FHKAM (Surgery)
Correspondence to: Dr JSK Pu
Email: ksjpu@hkucc.hku.hk
Jenny KS Pu
Raymond TT Chan
Gloria KB Ng 
Gilberto KK Leung
KN Hung
CF Fung
浦勤孫
陳子棠
吳幗寶	
梁嘉傑
洪君毅
馮正輝
Introduction
According to an ad-hoc survey of neurosurgical centres in Hong Kong carried out by the 
author with the assistance of The Hong Kong Neurosurgical Society, around 70 patients 
with high-grade malignant glioma (World Health Organization [WHO] grade III and IV) 
were seen by local neurosurgeons in the year July 2008 to July 2009. This gives an annual 
incidence of around 1 per 100 000 inhabitants. The most frequently encountered glioma 
subtype was glioblastoma multiforme (GBM), which constituted 5% of all brain tumours 
encountered in Hong Kong. Prognosis for patients with recurrent GBM is poor; the typical 
response rate to chemotherapy alone is 5 to 10% and yields a 6-month progression-free 
survival (PFS) of 10 to 24%.1 Surgery is commonly the initial therapeutic approach and aims 
to debulk the lesion and obtain a tissue diagnosis.2 In Hong Kong, the Stupp regimen3 has 
been widely adopted for post-surgical treatment of newly diagnosed malignant glioma. 
However, a standard therapeutic paradigm has yet to be established for recurrent malignant 
gliomas.2 Several recent publications report the use of the anti–vascular endothelial growth 
factor (VEGF) monoclonal antibody bevacizumab as a treatment for malignant glioma.4-12 
The potential for therapeutic benefit from using it in this disease is promising, as GBM 
tumours have been shown to secrete substantial amounts of VEGF in comparison to other 
tumour types.13 In phase II studies, bevacizumab administered as a single agent to patients 
New knowledge added by this study
• This is the first report on the efficacy and safety of bevacizumab in Asian patients with 
recurrent malignant gliomas.
Implications for clinical practice or policy
• Use of bevacizumab and irinotecan in combination may be a feasible treatment option for 
Asian patients with recurrent malignant gliomas.
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underwent resection and their cranial lesions were 
confirmed to be high-grade malignant gliomas by a 
certified pathologist. Patients received radiotherapy 
and chemotherapy after surgery. Bevacizumab 
and irinotecan were administered until disease 
progression or discontinuation due to complications, 
according to a schedule adapted from Vredenburgh 
et al.11 Bevacizumab (10 mg/kg) and irinotecan (125 
mg/m2 [dose modified to 340 mg/m2 for those taking 
enzyme-inducing antiepileptic drugs]) were both 
administered as an intravenous (IV) infusion on day 
1 of a 14-day schedule. Irinotecan was administered 
intravenously (>90 minutes) before IV bevacizumab 
(>30 minutes). 
 Post–contrast-enhanced magnetic resonance 
imaging (MRI) reports before surgery, post-surgery, 
after initial treatment and during treatment with 
bevacizumab and irinotecan were evaluated, and 
the exact tumour size was recorded according to 
the Response Evaluation Criteria in Solid Tumours 
(RECIST) criteria.21 Additional information from other 
imaging sequences including T2-weighted fast-spin 
echo and axial T2 fluid-attenuated inversion recovery 
(FLAIR) were taken into account when evaluating the 
response to bevacizumab and irinotecan. Radiologists 
who reviewed the images were all blinded to clinical 
outcomes. Response assessment was performed 
using MRI scans. Due to the retrospective nature of 
	 目的	 研究使用貝伐單抗（bevacizumab）聯合伊立替康
（irinotecan）治療惡性腦膠質瘤復發的華籍患者的療
效和安全性，以及研究他們的治療反應是否與其他國
家的患者不同。
	 設計	 回顧研究。 
	 安排	 香港其中兩間私立醫院及一間公立醫院。
	 患者	 2005年11月至2009年11月期間因復發性腦膠質瘤到
醫院求診的14名患者。
	 介入治療	 連續14天使用貝伐單抗（10 mg/kg）及伊立替康
（125 mg/m2 [正服用酶誘導抗癲癇藥物的病人的劑量
為340 mg/m2]）的搶救治療。 
	 結果	 12名（86%）患者對治療有影像學的反應，其中4名
（33%）有完全緩解跡象。無惡化生存期中位數為6
個月（介乎1至15個月）；有71%患者在治療後的6個
月內未有惡化。總存活率中位數為18個月（介乎9至
61個月）。治療期間最普遍的不良事件均與血液學有
關；5名患者出現不良事件的嚴重程度達2/3級。兩名
患者出現肺動脈栓塞，其中一人死亡。14名患者均未
有發現顱內出血。 
	 結論	 本研究結果顯示使用貝伐單抗聯合伊立替康治療惡性
腦膠質瘤復發的華籍患者，其療效與其他國家文獻中
報告的病人相若。
貝伐單抗治療惡性腦膠質瘤：
亞洲病人的初步結果
with recurrent GBM demonstrated objective benefits 
for a clinically meaningful duration (4-6 months).5,6 
Based upon that data, single-agent bevacizumab has 
been approved by the Food and Drug Administration 
and the Hong Kong Department of Health for the 
treatment for recurrent GBM.
 Response to temozolomide in patients with 
recurrent glioma is generally poor; in a phase II trial 
of continuous dose-intense use in patients with 
recurrent GBMs and anaplastic gliomas, 6-month PFS 
rates were 24% and 36%, respectively.14 In a study of 
Chinese patients with recurrent malignant gliomas 
in which 13 had GBMs and 9 had anaplastic gliomas, 
6-month PFS rates with temozolomide treatment 
were 21% and 46%, respectively, and the mean PFS 
for all glioma subtypes was 7 months.15 These data 
indicate that response to treatment in patients with 
recurrent gliomas was similar regardless of ethnicity. 
Although clinical data on treatment responses to 
bevacizumab in Chinese patients with recurrent 
glioma are scarce; a subgroup analysis of 198 Chinese 
patients with non–small-cell lung cancer enrolled in 
the SAiL trial gave similar median times to progression 
(TTP) and median overall survival (OS) values when 
compared to other populations; respective values 
for TTP were 8.8 vs 7.8 months, and for OS were 18.5 
vs 15.3 months.16 The safety profile of bevacizumab 
plus chemotherapy in the Chinese population was 
consistent with that reported in the global SAiL 
population,17 the E459918 and AVAiL trials.19 These 
data indicated that favourable clinical responses to 
bevacizumab might also be encountered in Chinese 
patients. Therefore, the objective of this paper was 
to review our local experience of bevacizumab 
as an adjuvant treatment in recurrent malignant 
glioma in Chinese patients, and how it compared 
to previous studies in the global population. To our 
knowledge, this is the first article to examine the use 
of bevacizumab in Asian patients with glioma.
Methods
Between November 2005 and November 2009, 
14 Hong Kong Chinese patients presenting with 
recurrent glioma at three centres (two private clinics 
and a public hospital) were treated with bevacizumab 
plus irinotecan. Bevacizumab was approved for use 
as a single agent in patients with relapsed GBM by the 
Department of Health in Hong Kong in September 
2009. These patients received salvage therapy with 
bevacizumab plus irinotecan, as an off-label drug, 
prior to this approval. Ethics committee approval was 
obtained from the University of Hong Kong for this 
treatment strategy and all patients provided written 
informed consent before receiving bevacizumab.
 Histological classification of high-grade 
malignant gliomas was performed according to the 
WHO brain tumour classification system.20 Patients 
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the study, assessment frequencies differed between 
patients but ranged from 4 to 10 weeks. Once the 
response category was determined (according 
to RECIST criteria), a confirmatory MRI scan was 
performed 4 to 6 weeks later. 
 Survival analyses were conducted using life 
tables and survival plots. The endpoints evaluated 
were the 6-month PFS, the overall response rate 
(ORR) and OS. Adverse events (AEs) were recorded 
and graded according to the National Cancer 
Institute (NCI) Common Terminology Criteria for 
Adverse Events version 3.0 (CTCAE). Any laboratory 
result anomaly fulfilling the criteria for a serious AE 
was also documented.
Results 
At diagnosis, multifocal tumours were present in nine 
patients, there being a total of 21 tumours in the 14 
patients; 13 tumours were located in eloquent areas 
and 8 in non-eloquent areas. Relevant demographic 
and clinical characteristics of these 14 patients 
are shown in Table 1, none of whom were lost to 
follow-up. At the time of receiving bevacizumab 
and irinotecan, two of the five patients with a single 
tumour had minimal residual disease, and three 
had gross residual disease. All nine patients with 
multifocal tumours were classified as having gross 
residual disease as it was not possible to remove all 
tumour tissue in one operation (Table 1).
 Radiological resolution was observed in 12 
patients giving an ORR of 86%; of these four had a 
complete response rate of 29%. The response rates 
for all 14 patients and the GBM subgroup are given in 
Table 2; corresponding survival analyses are shown 
in the Figure. Median PFS was 6 (range, 1-15) months 
with 71% remaining progression-free at 6 months. 
Median OS was 18 (range, 9-61) months. Subgroup 
analysis of GBM patients (n=11) yielded a median PFS 
of 6 (range, 1-15) months, with a 6-month PFS rate of 
64%. Median OS for patients with GBM was 17 (range, 
9-38) months.
 The most commonly observed AEs during 
salvage therapy with bevacizumab plus irinotecan 
were haematological, with five of the patients 
enduring grade 2/3 AEs according to CTCAE. 
Pulmonary embolism occurred in two patients, one of 
whom was fatal. Other common bevacizumab-related 
side-effects such as hypertension and proteinuria 
were also noted (Table 3). Intracranial haemorrhage 
was not detected in any of the 14 treated patients.
Discussion 
Bevacizumab in Asian patients
Previous data in metastatic/recurrent22 or previously 
untreated cancers19 have shown that bevacizumab 
*  MGMT denotes O-methylguanine DNA methyltransferase
Table 1. Patient characteristics at baseline
Patient characteristic No. of patients 
(n=14) 
Median (range) age (years) 50 (18-69)
Sex (male/female) 11/3
Histology
Glioblastoma multiforme 11
Anaplastic astrocytoma 1
Anaplastic oligodendroglioma 1
Anaplastic oligoastrocytoma 1
Tumour location
Eloquent cortex 13
Non-eloquent area 8
MGMT* methylation status
Positive 2
Negative 8
Unknown 3
Prior salvage treatment
Surgery 14
1 Procedure 5
2 Procedures 6
≥3 Procedures 3
Prior chemotherapy
Stupp regimen (completed) 12 (3)
Procarbazine, CCNU and vincristine 4
Residual disease at commencement 
of bevacizumab therapy
14
Minimal 2
*  Data are shown as No. (%) of patients, except otherwise indicated
Table 2. Response of treatment
 All patients 
(n=14)*
Glioblastoma 
multiforme 
(n=11)*
Overall response rate 12 (86) 9 (82)
Complete response 4 (29) 3 (27)
Partial response 8 (57) 6 (55)
Stable disease 0 0
Progressive disease 1 (7) 1 (9)
Unknown 1 (7) 1 (9)
Median progression-free survival (months) 6.0 6.0
Table 3. Most commonly observed adverse events during the 
bevacizumab and irinotecan treatment period
Adverse event No. of patients (n=14)
Haematological complication 5
Pulmonary embolism 2
Hypertension 2
Proteinuria 2
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is well-tolerated in Asians and that there is no racial 
difference in the pharmacokinetics of this drug. 
This current case series reports the first use of 
bevacizumab in Asian patients with glioma and shows 
that good objective responses were achieved. The 
6-month PFS observed in our series was comparable 
to previously published data on this condition from 
elsewhere.5,11 
Bevacizumab in recurrent gliomas
A pioneering study of bevacizumab in combination 
with irinotecan was the first to demonstrate a 
remarkable radiological response using contrast-
enhanced MRI in patients with recurrent malignant 
gliomas.10 In that series of 29 patients, the combination 
was well-tolerated and efficacious; 66% of those 
treated achieved a partial radiological response. 
These results were confirmed by a second small 
series of 14 patients23 and a retrospective review of 
data on 55 others with recurrent glioma.8 In the 14-
patient case series, the ORR as assessed by MRI was 
50%, all responses being partial.23 The retrospective 
review of 55 patients found that 2% of the patients 
achieved complete response, 32% achieved partial 
response, 30% had a minimal response, and 30% 
had stable disease (no change); the 6-month PFS 
and OS rates were 39% and 65%, respectively.8 The 
ORR of 86% in our patients was comparable to these 
data and indicated that ethnicity had no bearing 
on responsiveness to bevacizumab in patients with 
recurrent malignant glioma. The current case series 
had too few patients to allow robust comparison 
of PFS and OS data, although it does appear that 
responses in the Chinese patients are comparable to 
those reported in the populations.
Bevacizumab in recurrent glioblastoma multiforme
Recurrent GBM is associated with a dismal prognosis, 
with a 6-month PFS rate of 15% to 21% and a median 
survival of 25 weeks.1 In patients with relapsed GBM, 
current standard care with temozolomide has yielded 
a 6-month PFS of 21%, but with bevacizumab the 
response is more favourable with 6-month PFS rates 
of 32 to 64%.7,9,12 A significant breakthrough in the 
treatment of recurrent GBM came with the publication 
of Vredenburgh et al
,
s phase II prospective trial of 
FIG. Survival analyses with Kaplan-Meier methods
(a) Progression-free survival and (b) overall survival in all patients, and (c) progression-free survival and (d) overall survival in patients with glioblastoma 
multiforme
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bevacizumab and irinotecan (n=35).11 Such study 
reported a 6-month PFS rate of 46% and a 6-month 
OS rate of 77%, whilst 57% of the patients achieved 
at least a partial response. Later studies validated the 
efficacy and safety of single-agent bevacizumab in 
recurrent GBM. A report of an industry-sponsored 
phase II trial randomising 163 patients to treatment 
with either bevacizumab alone (n=84) or in 
combination with irinotecan (n =79) did not show any 
statistical difference between the arms.4 Whereas, in 
patients with recurrent GB, a phase II study of single-
agent bevacizumab followed by bevacizumab plus 
irinotecan at tumour progression conducted by the 
NCI, the former resulted in significant biologic and 
anti-glioma activity.6 These findings were confirmed 
in a large multicentre randomised non-comparative 
phase II study, in which 167 patients with recurrent 
GBM were randomised to either bevacizumab 
alone or in combination with irinotecan.5 The 
randomised design of this trial was intended to 
prevent bias in treatment assignment and no formal 
comparison of the two arms was planned. However, 
with bevacizumab alone or in combination with 
irinotecan, the ORR was 28% and 38%, respectively, 
and corresponding 6-month PFS rates were 43% and 
50%, whilst median PFS and OS rates were 4 and 9 
months as opposed to 6 and 9 months. In addition, 
bevacizumab as a single agent was associated with 
fewer discontinuations due to AEs.5 Subgroup 
analyses within our cohort found that the median 
PFS and 6-month PFS rate for the 11 patients with 
GBM were 6 months and 64%, respectively. Such 
findings compared favourably with the results 
discussed above and indicated that bevacizumab 
was a good treatment option for Chinese patients 
with recurrent GBM, the median OS for such 
patients being 17 months. As our estimate was based 
on a small number of patients, it should not be 
considered as robust. Nevertheless, the OS rate in 
our series was consistent with previously reported 
figures from two larger trials (with >80 patients) that 
both yielded median OS rates of 9 months,4,5 and 
from three smaller case series (each involving <40 
patients) that yielded medians ranging from 7 to 12 
months.9,11,12 
Assessment of response to bevacizumab therapy
When assessing the response in malignant 
glioma patients, bevacizumab’s mechanism of 
action presents a problem.24 The drug targets 
neovasculature, inhibiting regrowth.25 As it also 
normalises surviving tumour vasculature, it helps 
reduce cerebral oedema (caused by seepage from 
abnormal vessels).26 Thus, responses obtained 
from conventional imaging according to Modified 
Macdonald’s Criteria appeared very significant,27-29 
and is known as a ‘pseudoresponse’, which may 
in part explain the lack of a significant increase 
in survival despite the apparent response to anti-
angiogenic therapy.29 A recent update to the 
Macdonald criteria30 has suggested that, given the 
limitations of two-dimensional tumour assessments, 
volumetric tumour assessments may offer a more 
accurate measurement of lesions, though this may 
be difficult to achieve in routine clinical use and 
even in clinical trials involving treatment of brain 
tumours.24 The observation of linear changes in T2- 
or FLAIR-weighted MRI sequences (as employed in 
our case series) has been determined to be the best 
current method of assessing response in high-grade 
gliomas.24
Conclusions 
Salvage therapy with bevacizumab plus irinotecan 
appeared to be an effective treatment option in Hong 
Kong Chinese patients with recurrent malignant 
gliomas, and yielded a favourable 6-month PFS 
rate. Despite advances in the Macdonald criteria 
for malignant glioma, a number of questions still 
remain and the development of new techniques 
for assessment as well as investigations into the 
mechanisms of resistance may improve our ability 
to assess responses and treat those who develop 
cancers resistant to anti-angiogenic therapy.
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